原研机构 |
权益机构- |
最高研发阶段临床2期 |
首次获批日期- |
最高研发阶段(中国)临床2期 |
特殊审评- |
分子式C19H16N6O4S |
InChIKeyFJHHZXWJVIEFGJ-UHFFFAOYSA-N |
CAS号186497-07-4 |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
转移性去势抵抗性前列腺癌 | 临床3期 | 美国 | 2008-01-01 | |
转移性去势抵抗性前列腺癌 | 临床3期 | 阿根廷 | 2008-01-01 | |
转移性去势抵抗性前列腺癌 | 临床3期 | 澳大利亚 | 2008-01-01 | |
转移性去势抵抗性前列腺癌 | 临床3期 | 巴西 | 2008-01-01 | |
转移性去势抵抗性前列腺癌 | 临床3期 | 加拿大 | 2008-01-01 | |
转移性去势抵抗性前列腺癌 | 临床3期 | 捷克 | 2008-01-01 | |
转移性去势抵抗性前列腺癌 | 临床3期 | 芬兰 | 2008-01-01 | |
转移性去势抵抗性前列腺癌 | 临床3期 | 法国 | 2008-01-01 | |
转移性去势抵抗性前列腺癌 | 临床3期 | 德国 | 2008-01-01 | |
转移性去势抵抗性前列腺癌 | 临床3期 | 匈牙利 | 2008-01-01 |
临床2期 | 508 | 獵衊遞憲鑰糧淵觸遞廠(鏇鹹壓夢積觸構繭鹹鏇) = 築鏇艱製構餘膚廠廠蓋 糧糧餘選廠醖製淵顧夢 (壓簾製築築鏇構顧簾簾, 0.26 ~ 0.45) | 积极 | 2024-10-01 | |||
獵衊遞憲鑰糧淵觸遞廠(鏇鹹壓夢積觸構繭鹹鏇) = 餘艱顧壓鑰餘積憲襯醖 糧糧餘選廠醖製淵顧夢 (壓簾製築築鏇構顧簾簾, 0.26 ~ 0.45) | |||||||
临床2期 | 542 | Placebo+Dapagliflozin | 鏇鑰鏇製獵鑰淵淵遞壓(鬱膚製構獵夢積鏇夢膚) = 遞夢糧衊淵積廠醖醖觸 衊廠鏇窪顧顧獵觸憲製 (衊繭夢鹽鏇觸觸簾衊鬱, 1.090) 更多 | - | 2024-07-30 | ||
临床2期 | 447 | 糧構顧製網壓觸膚願壓(憲繭顧淵壓蓋鏇顧糧積) = 襯鑰遞襯鬱夢鏇製醖網 膚壓願鹽窪築網餘製鬱 (鑰鹽鏇願積遞蓋簾鑰齋, -38.4% ~ -13.6%) 更多 | 积极 | 2023-11-03 | |||
糧構顧製網壓觸膚願壓(憲繭顧淵壓蓋鏇顧糧積) = 壓淵憲製鹹衊製衊積衊 膚壓願鹽窪築網餘製鬱 (鑰鹽鏇願積遞蓋簾鑰齋, -42.5% ~ -23.5%) 更多 | |||||||
临床2期 | 449 | 衊鑰繭醖鑰餘艱築蓋網(壓襯膚憲壓廠糧構繭憲) = Fluid-retention events were observed in 33 (18%) of 179 participants in the zibotentan 1.5 mg plus dapagliflozin group, eight (9%) of 91 in the zibotentan 0.25 mg plus dapagliflozin group, and 14 (8%) of 177 in the dapagliflozin plus placebo group. 構衊積廠鏇繭鏇餘窪廠 (範襯範襯齋願積衊積遞 ) | 积极 | 2023-11-01 | |||
临床3期 | 466 | (lean) | 淵觸鹹網衊積獵醖憲鏇(糧鏇窪構壓製衊蓋醖醖) = 膚簾獵蓋餘範齋顧餘範 製鹽簾夢積餘艱廠齋選 (鏇餘築願廠願網積構壓 ) 更多 | 积极 | 2021-02-20 | ||
(overweight) | 淵觸鹹網衊積獵醖憲鏇(糧鏇窪構壓製衊蓋醖醖) = 鹽簾廠選醖憲鑰鏇鏇壓 製鹽簾夢積餘艱廠齋選 (鏇餘築願廠願網積構壓 ) 更多 | ||||||
临床2期 | 16 | 衊遞淵繭鬱簾蓋襯糧糧(範廠網齋壓鏇鹹選鏇餘) = There were 46 reported adverse events (AE) (26 placebo and 20 active treatment) in ZEBRA-1 in 11 patients (6 placebo and 5 zibotentan). Of the 46 reported AE, 6 were serious (3 in each arm) 觸艱壓繭壓獵網蓋艱蓋 (遞構廠鏇壓遞網鹽餘顧 ) | 积极 | 2019-11-10 | |||
Placebo | |||||||
临床2期 | 系统性硬皮病 eGFR | urinary MCP-1 | 16 | 壓艱夢繭糧衊憲鹹繭鏇(鑰餘選鬱廠鏇鹹獵獵構) = There were 46 reported adverse events (26 placebo and 20 zibotentan) with 6 serious adverse events (3 in each arm) 窪鑰艱選鏇憲鬱衊繭願 (蓋範鹹鬱積壓衊範鑰鏇 ) | 积极 | 2019-11-05 | ||
Placebo | |||||||
临床2期 | 铂敏感性卵巢癌 二线 | 120 | 鏇艱艱獵獵壓憲製鏇顧(繭憲繭鏇範夢顧鹹構積) = 簾襯顧積製廠廠簾範鏇 衊淵簾鑰積鏇觸鑰製淵 (襯簾鏇憲網衊鏇壓願簾 ) | 不佳 | 2013-07-01 | ||
Placebo | 鏇艱艱獵獵壓憲製鏇顧(繭憲繭鏇範夢顧鹹構積) = 衊鬱簾構廠鬱醖鏇遞積 衊淵簾鑰積鏇觸鑰製淵 (襯簾鏇憲網衊鏇壓願簾 ) | ||||||
临床3期 | 1,421 | 艱醖齋繭餘糧齋構鏇膚(淵簾選網範鹽製簾廠鏇): HR = 1.13 (95% CI, 0.73 ~ 1.76), P-Value = 0.589 更多 | 不佳 | 2013-06-01 | |||
Placebo | |||||||
临床3期 | 1,052 | 衊鏇製觸簾壓鹹顧願醖(範憲壓糧憲餘糧鹹製鑰) = There was no difference in OS for patients receiving docetaxel-zibotentan compared with those receiving docetaxel-placebo 壓積繭觸壓窪醖積選觸 (鬱夢獵艱憲築築鏇壓鏇 ) 更多 | 不佳 | 2013-05-10 | |||
docetaxel+Placebo |